Announcement
26 Mar 2020
In March 2020, the Norwegian authorities introduced a notification requirement on exports of four COVID-19 related pharmaceutical products.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
26 Mar 2020
Revocation date:
01 Jul 2023
Updated: 26 Mar 2020
Export licensing requirement
On 26 March 2020, the Norwegian Medicines Agency introduced a notification requirement on exports of four COVID-19 related pharmaceutical goods. These are immunoglobulin, salbutamol, fluticasone an...
Sign in to see more
Related State Acts
09 Jun 2020
Norway: Introduction and subsequent termination of export ban on certain immunoglobulins following the outbreak of COVID-19
05 Jun 2020
Norway: Introduction of export notification requirement on five pharmaceutical goods (COVID-19)
28 May 2020
Norway: Introduction and subsequent termination of export ban on immunoglobulin following the outbreak of COVID-19
Threads
See all
This state act is not part of any Thread yet.